Oxfordshire-based company Emergex will soon start clinical trials of a second-generation vaccine against COVID-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.

The vaccine will eventually be administered as a skin patch the size of a thumbnail bristling with micro-needles that release the shot within seconds.

英国牛津郡的Emergex公司将针对第二代新冠疫苗开展临床试验。

Emergex公司的这款疫苗利用T细胞杀死被感染的细胞，最终将以"拇指大小的皮肤贴片"形式接种，易于注射，且可以提供比现有疫苗更持久的免疫力。

当贴片接触皮肤时，上面的微型针头在几秒内就会把疫苗注入体内。

It can last for up to three months at room temperature, unlike other jabs that need to be stored in the freezer or fridge.

贴片疫苗与其他需存放在低温环境中的新冠疫苗不同，可以在室温下保存长达3个月。

Emergex has received the green light from the Swiss drugs regulator to conduct initial human trials in Lausanne starting on Jan 3.

Emergex公司已获得瑞士药品监管机构的批准，并将于明年1月3日开始在洛桑开展初期临床试验。

Interim results from the trial are expected in June.

试验的中期结果预计将于6月公布。

【英国研发贴片新冠疫苗查看网站：[db:时间]】